FATE (STOCKS)
Fate Therapeutics, Inc.
$1.182700
+0.092700 (+8.50%)
Prev close: $1.090000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Bahram Valamehr
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $134.96M
- Employees
- 181
- P/E (TTM)
- -0.89
- P/B (TTM)
- 0.58
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
6
Buy
7
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.27 | $-0.30 | +0.0269 | +9.06% |
|
Jun 2025 (Q2)
|
$-0.29 | $-0.35 | +0.0593 | +16.98% |
|
Mar 2025 (Q1)
|
$-0.32 | $-0.39 | +0.0707 | +18.10% |
|
Dec 2024 (Q4)
|
$-0.44 | $-0.44 | +0.0011 | +0.25% |
Financial Statements
| Revenues | $7.14M |
| Benefits Costs and Expenses | $129.24M |
| Costs And Expenses | $165.72M |
| Operating Expenses | $181.87M |
| Research and Development | $116.01M |
| Other Operating Expenses | $65.86M |
| Operating Income/Loss | -$174.73M |
| Income/Loss From Continuing Operations After Tax | -$156.09M |
| Income/Loss From Continuing Operations Before Tax | -$156.09M |
| Net Income/Loss | -$156.09M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$156.09M |
| Net Income/Loss Available To Common Stockholders, Basic | -$156.09M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.33 |
| Diluted Earnings Per Share | -$1.33 |
| Basic Average Shares | 120,016,122 |
| Diluted Average Shares | 120,016,122 |
| Assets | $343.67M |
| Current Assets | $221.25M |
| Noncurrent Assets | $122.42M |
| Fixed Assets | $59.48M |
| Other Non-current Assets | $62.95M |
| Liabilities | $109.61M |
| Current Liabilities | $28.11M |
| Accounts Payable | $3.50M |
| Other Current Liabilities | $24.61M |
| Noncurrent Liabilities | $81.49M |
| Equity | $234.07M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $234.07M |
| Liabilities And Equity | $343.67M |
| Net Cash Flow From Operating Activities | -$110.57M |
| Net Cash Flow From Operating Activities, Continuing | -$110.57M |
| Net Cash Flow From Investing Activities | $106.35M |
| Net Cash Flow From Investing Activities, Continuing | $106.35M |
| Net Cash Flow From Financing Activities | $6.93M |
| Net Cash Flow From Financing Activities, Continuing | $6.93M |
| Net Cash Flow | $2.71M |
| Net Cash Flow, Continuing | $2.71M |
| Comprehensive Income/Loss | -$156.78M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$156.78M |
| Other Comprehensive Income/Loss | -$682.00K |